Regenics are in collaboration with partners to expand the wound healing indication of Vernex to diabetic wounds. The collaboration involves both ongoing preclincial collaborations with US academic centres, established MoA (mechanism of action) studies of key skin cells relevant for diabetes chronic wounds as well as contractual options with large industrial players.

The indication has not been explored clinically at this stage. 




Scientifically documented and patented claims in diabetic chronic wounds (tbc):


Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.